PD35-09 HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) SCORE IN CHINESE AGGRESSIVE PROSTATIC ADENOCARCINOMA WITH OR WITHOUT INTRADUCTAL CARCINOMA OF THE PROSTATE

Abstract

You have accessJournal of UrologyCME1 May 2022PD35-09 HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) SCORE IN CHINESE AGGRESSIVE PROSTATIC ADENOCARCINOMA WITH OR WITHOUT INTRADUCTAL CARCINOMA OF THE PROSTATE Sha Zhu, and Hao Zeng Sha ZhuSha Zhu More articles by this author , and Hao ZengHao Zeng More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002593.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Homologous recombination deficiency (HRD) score manifests tumors’ genomic instability. Intraductal carcinoma of the prostate (IDC-P) is reported to be exceptionally genomically unstable. METHODS: This study investigates the landscape of HRD score distribution in a Chinese prostate cancer (PCa) cohort with a particular interest in IDC-P. This study included 123 PCa patients. HRD score is calculated based on over 10,000 single-nucleotide polymorphisms distributed across the human genome. We explored the association between HRD scores and clinicopathological characteristics, genomic alterations, and patients' prognoses using rank-sum tests, chi-square tests, Kaplan-Meier curves, and Cox proportional hazards method. RESULTS: The Median HRD score of this cohort is 21.0, with 70 (56.9%) patients showing HRD score ≥20. De novo metastatic (M1) (P =0.008), high ISUP grades (4-5) (P=0.001), and IDC-P (P=0.002) all correlated to high HRD scores. BRCA-mutated tumors displayed higher HRD scores than BRCA-wild type (wt) tumors (P=0.019). Nevertheless, the BRCA-wt group also showed a considerable amount of high (≥20) HRD score tumors (54.7%), and within this group, patients with IDC-P showed significantly higher HRD score (P=0.002). MYC mutations were associated with high HRD scores (P <0.001) in the total cohort. TP53 mutations (P=0.010) and HRR pathway mutations (P=0.028) corresponded to high HRD scores in IDC-P positive and non-IDC-P patients, respectively, but not vise versa. Patients with higher HRD scores seemed to progress faster with standard treatment (11.3 months vs. 28.0 months, P=0.077). M1, high Gleason score, and IDC-P pathology represent higher HRD scores in PCa. CONCLUSIONS: Tumors with IDC-P might have different driven mechanisms for high HRD scores than non-IDC-P. Alternative treatment should be considered for PCa patients with high HRD scores. Source of Funding: The Natural Science Foundation of China (NSFC 81902577); China Postdoctoral Science Foundation (2020M673239); The Research Foundation for the Postdoctoral Program of Sichuan University (2021SCU12014); Post-Doctor Research Project, West China Hospital, Sichuan University (20HXBH026) © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e630 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Sha Zhu More articles by this author Hao Zeng More articles by this author Expand All Advertisement PDF DownloadLoading ...